Cocktail

CompletedPhase 1

Drug Interaction Study Between AZD3480 and Cytochrome P450

A Phase I, Double Blind, Randomized, Two-Way Cross Over, Single- Centre Study in Healthy CYP2D6 Extensive Metabolizers and Poor Metabolizers to Investigate the Potential of AZD3480 to Inhibit Cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 Activity

Lead sponsor

AstraZeneca

Asset

AZD3480

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Alzheimer’s disease

Key I/E criteria

•Age 18-55•Male

Primary endpoint

•PK variables

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

Org study IDD3690C00016

SecondaryEudraCt nr 2007-002456-10

NCT IDNCT00692510

Timeline

Milestones

Study start2007-11 (month precision)

Study first posted2008-06-06estimated

Primary completion2008-09actual (month precision)

Study completion2008-09actual (month precision)

Last update posted2008-11-26estimated

Assets

Drug assets

AZD3480

Study populations

Who this study enrolls

Alzheimer’s disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age55 Years

SexMale

Healthy volunteersAccepted

Inclusion criteria

•Provision of signed written informed consent

•Clinically normal physical findings and laboratory values

Exclusion criteria

•Clinically significant illness or clinically relevant trauma within three weeks before the first dose

•History of clinically significant disease

•Use of prescribed medication during the 2 weeks before administration of the first dose of investigational product

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Safety / tolerability / PK

Other (unclassified)

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

Safety variables (adverse events, blood pressure, pulse, safety lab)

Time frame:During the whole treatment period

event count, event

Other (unclassified)

1 endpoint

Primary/protocol endpoint/low confidence

PK variables

Time frame:Frequent sampling occasions during the treatment periods

descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 21, 2026

Endpoint classificationDelfa ADRD endpoint taxonomy

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 21, 2026 snapshot.